Organization | Enzyvant Therapeutics GmbH

Enzyvant Therapeutics GmbH Report issue

For profit Phase 2

Founded: Cambridge MA United States (2016)

Status: Acquired by Sumitomo Dainippon (2019)

Organization Overview

First Clinical Trial

None

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Enzyvant Therapeutics GmbH | Enzyvant Therapeutics GmBH

Active Ingredients

Drugs in Phase 2 Trials (1)

cultured thymus tissue (Rethymic) (1 trial)

Drugs in Other Trials (7)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

basiliximab (Simulect) (1 trial)

cyclosporine (sandimmune) (1 trial)

methylprednisolone (medrol) (1 trial)

mycophenolate (CellCept) (1 trial)

prednisone (meticorten) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 8